$ARCT
Arcturus Therapeutics Holdings Inc.

2021 Q4 Form 10-K Financial Statement

#000156459022007832 Filed on March 01, 2022

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2021 Q2
Revenue $5.794M $2.437M $2.001M
YoY Change 158.89% 4.46% -13.82%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $10.81M $10.86M $10.04M
YoY Change 19.67% 94.97% 127.19%
% of Gross Profit
Research & Development $32.63M $45.40M $45.68M
YoY Change 34.37% 156.5% 475.01%
% of Gross Profit
Depreciation & Amortization $310.0K $289.0K $284.0K
YoY Change 14.81% 31.36% 35.24%
% of Gross Profit
Operating Expenses $32.63M $45.40M $45.68M
YoY Change 34.37% 156.5% 475.01%
Operating Profit -$37.65M -$53.82M -$53.72M
YoY Change 21.12% 157.05% 434.95%
Interest Expense -$1.018M -$263.0K -$861.0K
YoY Change 4990.0% 275.71% 291.36%
% of Operating Profit
Other Income/Expense, Net -$519.0K
YoY Change
Pretax Income -$38.66M -$54.08M -$54.58M
YoY Change 24.32% 157.54% 431.98%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$38.66M -$54.08M -$54.58M
YoY Change 24.3% 157.49% 431.82%
Net Earnings / Revenue -667.29% -2219.29% -2727.69%
Basic Earnings Per Share -$2.05
Diluted Earnings Per Share -$1.467M -$2.053M -$2.074M
COMMON SHARES
Basic Shares Outstanding 26.34M
Diluted Shares Outstanding 26.34M

Balance Sheet

Concept 2021 Q4 2021 Q3 2021 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $370.5M $413.9M $433.6M
YoY Change -19.96% 34.81% 218.57%
Cash & Equivalents $370.5M $413.9M $433.6M
Short-Term Investments
Other Short-Term Assets $5.102M $5.071M $2.301M
YoY Change 82.21% 10.24% -25.77%
Inventory
Prepaid Expenses
Receivables $3.367M $2.015M $2.163M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $379.0M $421.0M $438.0M
YoY Change -18.99% 34.02% 208.48%
LONG-TERM ASSETS
Property, Plant & Equipment $5.643M $4.843M $3.407M
YoY Change 67.05% -41.65% -56.32%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $515.0K $670.0K $920.0K
YoY Change
Other Assets $2.077M $2.074M $107.0K
YoY Change 1977.0% 1974.0% 7.0%
Total Long-Term Assets $13.85M $13.57M $10.78M
YoY Change 59.84% 61.55% 36.39%
TOTAL ASSETS
Total Short-Term Assets $379.0M $421.0M $438.0M
Total Long-Term Assets $13.85M $13.57M $10.78M
Total Assets $392.8M $434.5M $448.8M
YoY Change -17.56% 34.74% 199.41%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $10.06M $8.265M $10.08M
YoY Change -6.65% 27.15% 129.18%
Accrued Expenses $23.52M $52.36M $42.61M
YoY Change 21.32% 336.32% 460.71%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $22.47M $18.48M $5.000M
YoY Change 1697.92%
Total Short-Term Liabilities $99.54M $118.2M $70.77M
YoY Change 101.0% 322.28% 207.69%
LONG-TERM LIABILITIES
Long-Term Debt $40.63M $42.35M $56.31M
YoY Change 193.49% 180.43% 272.91%
Other Long-Term Liabilities $24.43M $14.83M $16.09M
YoY Change 48.08% -16.71% -12.57%
Total Long-Term Liabilities $40.63M $57.17M $72.40M
YoY Change 193.49% 73.77% 116.11%
TOTAL LIABILITIES
Total Short-Term Liabilities $99.54M $118.2M $70.77M
Total Long-Term Liabilities $40.63M $57.17M $72.40M
Total Liabilities $164.6M $175.4M $143.2M
YoY Change 106.0% 188.03% 153.39%
SHAREHOLDERS EQUITY
Retained Earnings -$347.5M -$308.8M -$254.7M
YoY Change 141.66%
Common Stock $26.00K
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $228.2M $259.1M $305.6M
YoY Change
Total Liabilities & Shareholders Equity $392.8M $434.5M $448.8M
YoY Change -17.56% 34.74% 199.41%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2021 Q2
OPERATING ACTIVITIES
Net Income -$38.66M -$54.08M -$54.58M
YoY Change 24.3% 157.49% 431.82%
Depreciation, Depletion And Amortization $310.0K $289.0K $284.0K
YoY Change 14.81% 31.36% 35.24%
Cash From Operating Activities -$42.50M -$16.65M -$32.94M
YoY Change 540.98% 4.87% 288.02%
INVESTING ACTIVITIES
Capital Expenditures -$1.118M -$1.766M -$402.0K
YoY Change 62.03% 301.36% -14.47%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$1.118M -$1.766M -$402.0K
YoY Change 62.03% 301.36% -14.47%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 230.0K 692.0K 84.00K
YoY Change -99.86% -99.63% -99.9%
NET CHANGE
Cash From Operating Activities -42.50M -16.65M -32.94M
Cash From Investing Activities -1.118M -1.766M -402.0K
Cash From Financing Activities 230.0K 692.0K 84.00K
Net Change In Cash -43.39M -17.73M -33.26M
YoY Change -127.83% -110.37% -143.4%
FREE CASH FLOW
Cash From Operating Activities -$42.50M -$16.65M -$32.94M
Capital Expenditures -$1.118M -$1.766M -$402.0K
Free Cash Flow -$41.38M -$14.89M -$32.54M
YoY Change 596.62% -3.58% 305.75%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
26372000
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
26372000
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
26192000
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
26192000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
26000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
26000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
575675000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
540343000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
228211000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
396553000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
392814000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
476456000
CY2021 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
12359000
CY2020 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
9539000
CY2019 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
20789000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
173760000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
57846000
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
33640000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
41451000
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
23217000
CY2019 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12662000
CY2021 us-gaap Operating Expenses
OperatingExpenses
215211000
CY2020 us-gaap Operating Expenses
OperatingExpenses
81063000
CY2019 us-gaap Operating Expenses
OperatingExpenses
46302000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-202852000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-71524000
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-25513000
CY2021 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
515000
CY2020 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-263000
CY2019 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-32000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2011000
CY2021 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
584000
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-769000
CY2019 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1675000
CY2020 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
7041000
CY2019 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
240000
CY2019 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
8970000
CY2019 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-446000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-135043000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-347500000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-143800000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-42861000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6445000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3406000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1742000
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
818000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3406000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1742000
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-818000
CY2021 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
46599000
CY2019 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
4945000
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
902000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-203674000
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2726000
CY2019 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
139000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-25991000
CY2021 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
515000
CY2020 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
423819000
CY2019 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
21278000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
48016000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
436145000
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1982000
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
41907000
CY2019 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
21278000
CY2019 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
139000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-90433000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
25792000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-72148000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
391542000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6764000
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
34644000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
463002000
CY2020 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
423819000
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2726000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
71460000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
28915000
CY2021 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
5000000
CY2021 arct Stock Issued During Period Value Under Equity Plan
StockIssuedDuringPeriodValueUnderEquityPlan
515000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
228211000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-203674000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-72148000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-25991000
CY2021 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1193000
CY2020 us-gaap Depreciation And Amortization
DepreciationAndAmortization
882000
CY2021 arct Net Operating Loss And Research And Development Credit Carryforwards Limitations On Cumulative Change In Ownership Period
NetOperatingLossAndResearchAndDevelopmentCreditCarryforwardsLimitationsOnCumulativeChangeInOwnershipPeriod
P3Y
CY2019 us-gaap Accounting Standards Update Extensible List
AccountingStandardsUpdateExtensibleList
http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate201409Member
CY2020Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent
CY2019 us-gaap Depreciation And Amortization
DepreciationAndAmortization
684000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
28915000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
6764000
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
1982000
CY2021 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
5000000
CY2021 arct Gain Loss From Equity Method Investment
GainLossFromEquityMethodInvestment
515000
CY2020 arct Gain Loss From Equity Method Investment
GainLossFromEquityMethodInvestment
-263000
CY2019 arct Gain Loss From Equity Method Investment
GainLossFromEquityMethodInvestment
-25000
CY2021 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
577000
CY2021 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-3382000
CY2020 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-162000
CY2019 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-873000
CY2021 dei Auditor Firm
AuditorFirmId
42
CY2021 dei Auditor Name
AuditorName
Ernst & Young, LLP
CY2021 dei Auditor Location
AuditorLocation
San Diego, California
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
370492000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
462895000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3367000
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2125000
CY2021Q4 arct Prepaid Expenses And Other Receivables
PrepaidExpensesAndOtherReceivables
5102000
CY2020Q4 arct Prepaid Expenses And Other Receivables
PrepaidExpensesAndOtherReceivables
2769000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
378961000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
467789000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5643000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3378000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5618000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5182000
CY2021Q4 us-gaap Equity Method Investments
EquityMethodInvestments
515000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2077000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
107000
CY2021Q4 us-gaap Assets
Assets
392814000
CY2020Q4 us-gaap Assets
Assets
476456000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
10058000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
10774000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
23523000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
19389000
CY2021Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
22474000
CY2020Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
1250000
CY2021Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
43482000
CY2020Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
18108000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
99537000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
49521000
CY2021Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
19931000
CY2020Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
12512000
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
40633000
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
13845000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4502000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4025000
CY2021Q4 us-gaap Liabilities
Liabilities
164603000
CY2020Q4 us-gaap Liabilities
Liabilities
79903000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-347490000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-143816000
CY2021 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1242000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
372600000
CY2020 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-54000
CY2019 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2302000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2333000
CY2019 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2021 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2100000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
100000
CY2021Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0
CY2021 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentration of Credit Risk and Significant Customers</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments, which potentially subject the Company to concentrations of credit risk, consist of cash and cash equivalents. The Company limits its exposure to credit loss by placing its cash and cash equivalents with high credit quality financial institutions in instruments with short maturities. </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were two customers that comprised 100% of the total accounts receivable balance at December 31, 2021 and one customer that comprised 100% of the total accounts receivable balance at December 31, 2020. </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the year ended December 31, 2021, the Company’s top four customers<span style="color:#000000;"> collectively </span>represented 99% of the Company’s total revenue. For the year ended December 31, 2020, there were four customers that collectively represented 94% of the Company’s total revenue. </p>
CY2021 arct Upfront Fee And Consideration
UpfrontFeeAndConsideration
9200000
CY2021Q4 us-gaap Equity Method Investment Aggregate Cost
EquityMethodInvestmentAggregateCost
9200000
CY2021 us-gaap Payments To Acquire Interest In Joint Venture
PaymentsToAcquireInterestInJointVenture
0
CY2021Q4 arct Percentage Of Equity Interest In Joint Venture
PercentageOfEquityInterestInJointVenture
0.49
CY2021 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2020 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2021 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
0
CY2020 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
0
CY2019 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
0
CY2021 us-gaap Other Comprehensive Income Loss Available For Sale Securities Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax
0
CY2020 us-gaap Other Comprehensive Income Loss Available For Sale Securities Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax
0
CY2019 us-gaap Other Comprehensive Income Loss Available For Sale Securities Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax
0
CY2021 us-gaap Dividends
Dividends
0
CY2020 us-gaap Dividends
Dividends
0
CY2020Q4 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
2125000
CY2021 arct Contract With Customer Asset Additions For Revenue Recognized
ContractWithCustomerAssetAdditionsForRevenueRecognized
35152000
CY2021 arct Contract With Customer Asset Deductions For Cash Collections
ContractWithCustomerAssetDeductionsForCashCollections
-33910000
CY2021Q4 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
3367000
CY2020Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
30620000
CY2021 arct Contract With Customer Liability Additions For Advanced Billings
ContractWithCustomerLiabilityAdditionsForAdvancedBillings
45152000
CY2021 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
-12359000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
370492000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
462895000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
71353000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2077000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
107000
CY2019Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
107000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
372569000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
463002000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
71460000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2097000
CY2021Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
63413000
CY2021 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
12359000
CY2020 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
9539000
CY2019 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
20789000
CY2020Q4 arct Accrued Cystic Fibrosis Foundation Liability
AccruedCysticFibrosisFoundationLiability
6585000
CY2020Q4 arct Accrued Singapore Economic Development Board Liability
AccruedSingaporeEconomicDevelopmentBoardLiability
1761000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1630000
CY2020Q4 arct Clinical Accruals Current
ClinicalAccrualsCurrent
4067000
CY2020Q4 arct Other Accrued Research And Development Expenses
OtherAccruedResearchAndDevelopmentExpenses
3249000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
19389000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
9899000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
6441000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4256000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3063000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5643000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3378000
CY2020 us-gaap Depreciation And Amortization
DepreciationAndAmortization
900000
CY2019 us-gaap Depreciation And Amortization
DepreciationAndAmortization
700000
CY2021Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
6666667
CY2021Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
8633333
CY2021Q4 us-gaap Long Term Debt
LongTermDebt
15300000
CY2021 us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
2700000
CY2020 us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
900000
CY2019 us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
900000
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1261112
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1157175
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
138377
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
3600000
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
20200000
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
100000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
28915000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6764000
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1982000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-203674000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-72148000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-25922000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-69000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-72148000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-25991000
CY2021 arct Maximum Percentage Of Likelihood Of Uncertain Tax Position Recognized To Be Sustained
MaximumPercentageOfLikelihoodOfUncertainTaxPositionRecognizedToBeSustained
0.50
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1500000
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
400000
CY2018Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
400000
CY2021 us-gaap Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities
UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
0
CY2020 us-gaap Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities
UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
0
CY2019 us-gaap Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities
UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
0
CY2021 arct Unrecognized Tax Benefits Decreases Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesIncreasesResultingFromPriorPeriodTaxPositions
-100000
CY2020 arct Unrecognized Tax Benefits Decreases Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesIncreasesResultingFromPriorPeriodTaxPositions
300000
CY2019 arct Unrecognized Tax Benefits Decreases Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesIncreasesResultingFromPriorPeriodTaxPositions
0
CY2021 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
1000000.0
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
800000
CY2019 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
0
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
2400000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1500000
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
400000
CY2019Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
0
CY2020Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
0
CY2021Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
0
CY2021 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2020 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2019 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
69761000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
33896000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
11020000
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
6278000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
910000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
535000
CY2021Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
5098000
CY2020Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
3230000
CY2021Q4 us-gaap Deferred Tax Assets Inventory
DeferredTaxAssetsInventory
5850000
CY2021Q4 us-gaap Deferred Tax Assets Equity Method Investments
DeferredTaxAssetsEquityMethodInvestments
1957000
CY2021Q4 arct Deferred Tax Assets Property Plant And Equipment And Intangible Assets
DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets
960000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
100887000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
46551000
CY2020Q4 arct Deferred Tax Liabilities Property Plant And Equipment And Intangible Assets
DeferredTaxLiabilitiesPropertyPlantAndEquipmentAndIntangibleAssets
69000
CY2021Q4 arct Deferred Tax Liabilities Right Of Use Asset
DeferredTaxLiabilitiesRightOfUseAsset
1265000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
6039000
CY2021Q4 arct Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
1360000
CY2020Q4 arct Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
1274000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
3971000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1338000
CY2020Q4 arct Deferred Tax Liabilities Right Of Use Asset
DeferredTaxLiabilitiesRightOfUseAsset
1168000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
99622000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
45314000
CY2021 arct Federal Net Operating Losses Offset Percent
FederalNetOperatingLossesOffsetPercent
0.80
CY2021 arct Net Operating Loss And Research And Development Credit Carryforwards Limitations On Cumulative Change In Ownership Minimum Percentage
NetOperatingLossAndResearchAndDevelopmentCreditCarryforwardsLimitationsOnCumulativeChangeInOwnershipMinimumPercentage
0.50
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.062
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.068
CY2019 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.046
CY2019 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0.003
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.004
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.055
CY2019 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.001
CY2021 arct Effective Income Tax Rate Reconciliation Nondeductible Expense Officers Compensation
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOfficersCompensation
-0.011
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
0.029
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
0.087
CY2021 arct Effective Income Tax Rate Reconciliation Uncertain Tax Position
EffectiveIncomeTaxRateReconciliationUncertainTaxPosition
-0.004
CY2020 arct Effective Income Tax Rate Reconciliation Uncertain Tax Position
EffectiveIncomeTaxRateReconciliationUncertainTaxPosition
-0.015
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.017
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.015
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.001
CY2020 us-gaap Effective Income Tax Rate Reconciliation Repatriation Of Foreign Earnings
EffectiveIncomeTaxRateReconciliationRepatriationOfForeignEarnings
0.285
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.267
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.674
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.251
CY2021 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Other
EffectiveIncomeTaxRateReconciliationTaxCreditsOther
0.002
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Other
EffectiveIncomeTaxRateReconciliationTaxCreditsOther
-0.001
CY2019 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Other
EffectiveIncomeTaxRateReconciliationTaxCreditsOther
0.001
CY2019 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.007
CY2020Q1 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P13M
CY2021Q1 arct Monthly Base Rent
MonthlyBaseRent
11000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1987000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2185000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2251000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
522000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
6945000
CY2021Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
906000
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y3M
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.084
CY2021 us-gaap Operating Lease Cost
OperatingLeaseCost
1900000
CY2020 us-gaap Operating Lease Cost
OperatingLeaseCost
1900000
CY2019 us-gaap Operating Lease Cost
OperatingLeaseCost
1200000
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2127000
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2001000
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2437000
CY2021Q4 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
5794000
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
50050000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
45679000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
45398000
CY2021Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
32633000
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9743000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10042000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10860000
CY2021Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10806000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-57666000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-53720000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-53821000
CY2021Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-37645000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-56346000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-54581000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-54084000
CY2021Q4 us-gaap Net Income Loss
NetIncomeLoss
-38663000
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.15
CY2021Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.07
CY2021Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.05
CY2021Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.47
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
26243000
CY2021Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
26323000
CY2021Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
26338000
CY2021Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
26359000
CY2020Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2646000
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2322000
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2333000
CY2020Q4 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2238000
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7917000
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7944000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17699000
CY2020Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24286000
CY2020Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4191000
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4420000
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5572000
CY2020Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9034000
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-9462000
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-10042000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-20938000
CY2020Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-31082000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-9777000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-10263000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-21004000
CY2020Q4 us-gaap Net Income Loss
NetIncomeLoss
-31104000
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.67
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.55
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.92
CY2020Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.25
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
14521000
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
18794000
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
22938000
CY2020Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
24886000

Files In Submission

Name View Source Status
0001564590-22-007832-index-headers.html Edgar Link pending
0001564590-22-007832-index.html Edgar Link pending
0001564590-22-007832.txt Edgar Link pending
0001564590-22-007832-xbrl.zip Edgar Link pending
arct-10k_20211231.htm Edgar Link pending
arct-10k_20211231_htm.xml Edgar Link completed
arct-20211231.xsd Edgar Link pending
arct-20211231_cal.xml Edgar Link unprocessable
arct-20211231_def.xml Edgar Link unprocessable
arct-20211231_lab.xml Edgar Link unprocessable
arct-20211231_pre.xml Edgar Link unprocessable
arct-ex231_7.htm Edgar Link pending
arct-ex311_12.htm Edgar Link pending
arct-ex312_11.htm Edgar Link pending
arct-ex313_10.htm Edgar Link pending
arct-ex321_6.htm Edgar Link pending
arct-ex322_8.htm Edgar Link pending
arct-ex323_14.htm Edgar Link pending
arct-ex41_15.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gpgpmudqk3bd000001.jpg Edgar Link pending
gpgpmudqk3bd000002.jpg Edgar Link pending
gpgpmudqk3bd000003.jpg Edgar Link pending
gpgpmudqk3bd000004.jpg Edgar Link pending
gpgpmudqk3bd000005.jpg Edgar Link pending
gpgpmudqk3bd000006.jpg Edgar Link pending
gpgpmudqk3bd000007.jpg Edgar Link pending
gpgpmudqk3bd000008.jpg Edgar Link pending
gpgpmudqk3bd000009.jpg Edgar Link pending
gpgpmudqk3bd000010.jpg Edgar Link pending
gpgpmudqk3bd000011.jpg Edgar Link pending
gpgpmudqk3bd000012.jpg Edgar Link pending
gpgpmudqk3bd000013.jpg Edgar Link pending
gpgpmudqk3bd000014.jpg Edgar Link pending
gpgpmudqk3bd000015.jpg Edgar Link pending
gpgpmudqk3bd000016.jpg Edgar Link pending
gpgpmudqk3bd000017.jpg Edgar Link pending
gpgpmudqk3bd000018.jpg Edgar Link pending
gpgpmudqk3bd000019.jpg Edgar Link pending
gpgpmudqk3bd000020.jpg Edgar Link pending
gpgpmudqk3bd000021.jpg Edgar Link pending
gpgpmudqk3bd000022.jpg Edgar Link pending
gpgpmudqk3bd000023.jpg Edgar Link pending
gpgpmudqk3bd000024.jpg Edgar Link pending
gpgpmudqk3bd000025.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending